Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma

NCT07744529 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Leptomeningeal Metastasis From Lung Cancer

Interventions

DRUG: Amivantamab+ systemic/ intrathecal Pemetrexed

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine